Bank of America is making a $1 million anchor grant to Virginia Commonwealth University’s (VCU) College of Engineering. The grant will support ongoing programs that expand access for students to pursue a technology education, engage thousands of K-12 students in engineering outreach experiences and increase teacher participation in professional development sessions. This grant is the …

ivWatch, LLC, inventor of the first and only continuous IV infiltration detection technology, appointments Kathy Cox to Chief Financial Officer. With over 23 years of experience, including 15 years in the medical device manufacturing and healthcare markets, Cox will strengthen the ivWatch leadership team and will provide expertise in driving business growth and operational efficiencies. …

A 2021 report by the U.S. Department of Health and Human Services found that Veterans are significantly more likely to develop multiple chronic health conditions in their lifetime like hypertension, arthritis, and cancer compared to non-Veterans. [1] To help treat wounded warriors and keep the military community healthy, we feel we must seek to identify …

AgroSpheres, Inc. progresses toward a key milestone in reducing pesticide impact in the environment. The submission of AgroSpheres™ Inert ingredient to the US Environmental Protection Agency (EPA) for use in agriculture inputs will further the company’s objective to make biopesticides more effective and reduce the rates of synthetic pesticide application. When approved, this technology will …

The National Institutes of Health (NIH) Office of Research on Women’s Health (ORWH) is planning a Women’s Health Consensus Conference (WHCC) in October 2021, in response to a Congressional request to address NIH research efforts related to women’s health research as well as the following specific conditions, rising maternal morbidity and mortality rates, increasing rates …

CEL-SCI Corporation released results from its 9.5 year pivotal Phase 3 study for its immunotherapy Multikine® (Leukocyte Interleukin, Injection)* in the treatment of advanced (stages III and IV) primary (previously untreated) squamous cell carcinoma of the head and neck (SCCHN). In the intent to treat (ITT) advanced primary SCCHN patients the study showed a statistically …